Peptide · Inhibitor of Complement C5 (C5) · developed by Rallybio
RLYB116 is a small protein built from an Affibody Z-domain that binds complement C5 with high affinity and inhibits terminal complement activation, plus an albumin-binding domain that extends its plasma half-life. It is being studied in hematologic diseases and autoimmune diseases.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06797375 | Phase 1 | Hematologic Diseases | Completed | RLYB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Autoimmune DiseasesHematologic Diseases
Updated Nov 1, 2026. Something wrong or missing? Report it on the RLYB page.
See RLYB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RLYB catalysts and pipeline →